MustGrow Biologics (DE:0C0)
FRANKFURT:0C0
0C0 Stock Chart & Stats
€0.33
-€0.13(-11.93%)
At close: 4:00 PM EST
€0.33
-€0.13(-11.93%)
Day’s Range― - ―
52-Week Range€0.25 - €0.59
Previous CloseN/A
Volume0.00
Average Volume (3M)1.45K
Market Cap
€16.31M
Enterprise Value€26.32M
Total Cash (Recent Filing)€419.58K
Total Debt (Recent Filing)€553.41K
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding62,959,820
10 Day Avg. Volume1,312
30 Day Avg. Volume1,447
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)39.49
Price to Sales (P/S)4.13
P/FCF Ratio-5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€15.68M
Bulls Say, Bears Say
Bulls Say
Moderate LeverageDebt-to-equity near 0.67 indicates leverage is not extreme, which preserves financial flexibility relative to highly leveraged peers. Over a 2–6 month horizon this reduces immediate interest burden risk and makes external financing or restructuring less constrained if cash burn continues.
Biologic-focused Product & Partnering ModelA product-led, biologic crop-protection model with an explicit partnering distribution strategy reduces capital intensity for market rollouts. Durable advantages include IP-led product differentiation and lower go-to-market CAPEX by leveraging partners for regulatory and commercial scale.
Prior Commercial Scale DemonstratedHaving reached roughly $8.3M revenue in 2025 demonstrates commercial traction and that the platform can generate meaningful sales. This historic scale provides a foundation for recovery if product commercialization and cost structure stabilization are executed.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicates the business is consuming capital and likely reliant on external funding to sustain operations. Over months this raises dilution and refinancing risk and limits the firm's ability to invest in commercialization or scale production.
Sharp Revenue Decline And VolatilityA 44% TTM revenue decline signals volatile demand or execution challenges. Persistent top-line contraction undermines operating leverage, increases unit economics uncertainty, and makes multi-quarter planning and R&D prioritization riskier for durable growth.
Deep, Persistent Losses And Eroded EquityVery large negative margins and sharply eroded equity indicate persistent unprofitability and weakened balance sheet capacity. Over a multi-month horizon this constrains strategic options, increases insolvency risk if cash needs persist, and weakens bargaining power with partners and investors.
MustGrow Biologics News
0C0 FAQ
What was MustGrow Biologics’s price range in the past 12 months?
MustGrow Biologics lowest stock price was €0.25 and its highest was €0.59 in the past 12 months.
What is MustGrow Biologics’s market cap?
MustGrow Biologics’s market cap is €16.31M.
When is MustGrow Biologics’s upcoming earnings report date?
MustGrow Biologics’s upcoming earnings report date is Aug 20, 2026 which is in 62 days.
How were MustGrow Biologics’s earnings last quarter?
Currently, no data Available
Is MustGrow Biologics overvalued?
According to Wall Street analysts MustGrow Biologics’s price is currently Overvalued.
Does MustGrow Biologics pay dividends?
MustGrow Biologics does not currently pay dividends.
What is MustGrow Biologics’s EPS estimate?
MustGrow Biologics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MustGrow Biologics have?
MustGrow Biologics has 62,959,820 shares outstanding.
What happened to MustGrow Biologics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MustGrow Biologics?
Currently, no hedge funds are holding shares in DE:0C0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MustGrow Biologics
MustGrow Biologics Corp. is an agricultural biotechnology enterprise specializing in the creation and commercialization of natural crop protection solutions. These offerings, including biopesticides, biofumigants, and bioherbicides, are uniquely derived from mustard seed. The company provides a pre-planting soil biofumigation technique aimed at combating soil-borne diseases and pests across diverse agricultural commodities, such as fruits and vegetables. Furthermore, MustGrow is actively developing a bioherbicide to manage undesirable plant growth, intended for use in organic farming, home gardens, and broader agricultural sectors. Their portfolio also extends to post-harvest food preservation, applying treatments to inhibit sprouting, disease, and pathogens, thereby enhancing the shelf life of stored products. A significant offering is CannaPM, an active compound effective against both fungal soil ailments and foliar diseases. Established in 2014 and headquartered in Saskatoon, Canada, the company adopted the name MustGrow Biologics Corp. in March 2018, having previously operated as Duport Capital Ltd.
0C0 Earnings Call
Q1 2026
0:00 / 0:00
Technical Analysis
Progressive Planet Solutions Inc
―
Bee Vectoring Technologies International
―
Gensource Potash
―
Verde Agritech
―
Nutrien
―
Options Prices
Currently, No data available
---